中国生物工程杂志

[1] Fukazawa T, Matsuoka J, Yamatsuji T, et al. Adenovirus-mediated cancer gene therapy and virotherapy. Int J Mol Med, 2010, 25(1):3-10.

[2] Ma X J, Huang R, Kuang A R. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Cancer Invest, 2009, 27(6):673-681.

[3] Thieringer F R, Maass T, Anthon B, et al. Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. Mol Carcinog, 2011 Jun 16.

[4] Cao X, Yang M, Wei R C, et al. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Gene Ther, 2011, 18(8):765-777.

[5] Klutz K, Willhauck M J, Wunderlich N, et al. Sodium Iodide Symporter (NIS)-Mediated Radionuclide Therapy of Liver Cancer After Transcriptionally Targeted Intratumoral in Vivo NIS Gene Delivery. Hum Gene Ther,2011 Jun 28.

[6] Chen L, Zheng J, Zhang Y, et al. Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther, 2011, 19(8):1521-1528.

[7] Kim S I, Shin D, Lee H, et al. Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. J Hepatol, 2009,50(3):479-488.

[8] Argyros O, Wong S P, Niceta M, et al. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther, 2008, 15(24):1593-1605.

[9] Lam P Y, Sia K C, Khong J H, et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther, 2007, 15(6):1129-1136.

[10] Miao C H, Ohashi K, Patijn G A, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther, 2000, 1(6):522-532.

[11] Kramer M G, Barajas M, Razquin N,et al. In vitro and in vivo comparative study of chimeric liver-specific promoters. Mol Ther, 2003, 7(3):375-385.

[12] Mawatari F, Tsuruta S, Ido A,et al. Retrovirus-mediated gene therapy for hepatocellular carcinoma:selective and enhanced suicide gene expression regulated by human alpha-fetoprotein enhancer directly linked to its promoter. Cancer Gene Ther, 1998, 5(5):301-306.

[13] Ishikawa H, Nakata K, Mawatari F, et al. Retrovirus-mediated gene therapy for hepatocellular carcinoma with reversely oriented therapeutic gene expression regulated by alpha-fetoprotein enhancer/promoter. Biochem Biophys Res Commun, 2001, 287(4):1034-1040.

[14] Kay M A, Li Q, Liu T J,et al. Hepatic gene therapy:persistent expression of human alpha 1-antitrypsin in mice after direct gene delivery in vivo. Hum Gene Ther, 1992, 3(6):641-647.

[15] Hafenrichter D G, Wu X, Rettinger S D, et al. Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes. Blood, 1994, 84(10):3394-3404.

[16] Lam P Y, Sia K C, Khong J H, et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther, 2007, 15(6):1129-1136.